China's first case of human cd19car-t cell treatment of leukemia has been successful!
-
Last Update: 2016-04-14
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: biological exploration 2016-4-14 in recent years, tumor immunotherapy has entered a rapid development stage As one of the important methods, car-t therapy has achieved very encouraging results in hematological cancer treatment At present, more and more domestic enterprises, hospitals and academic institutions join in this research field to jointly promote the development of car-t therapy and explore more extensive potential application value Recently, a good news came from the Affiliated Hospital of Xuzhou Medical College, where the first car-t targeting CD19 was successfully used to treat acute lymphoblastic leukemia (all) It is reported that the patient used a modified version of car-t cells, and its scFv sequence was humanized, which has the characteristics of low immunogenicity in vivo, not being recognized by the autoimmune system, and long survival time in vivo This trial is the first reported case of complete remission of all treated with humanized cd19car-t in China.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
